Royce & Associates LP Buys 59,513 Shares of Castle Biosciences, Inc. $CSTL

Royce & Associates LP purchased a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 59,513 shares of the company’s stock, valued at approximately $2,114,000. Royce & Associates LP owned 0.19% of Castle Biosciences at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Castle Biosciences during the second quarter worth $78,513,000. Jefferies Financial Group Inc. acquired a new stake in shares of Castle Biosciences in the 2nd quarter valued at $15,440,000. Renaissance Technologies LLC increased its stake in shares of Castle Biosciences by 8.1% in the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after purchasing an additional 39,700 shares during the last quarter. AIGH Capital Management LLC bought a new position in shares of Castle Biosciences in the 2nd quarter valued at $13,001,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Castle Biosciences during the 2nd quarter worth $7,912,000. 92.60% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Castle Biosciences news, insider Derek J. Maetzold sold 12,428 shares of the stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $33.20, for a total value of $412,609.60. Following the completion of the transaction, the insider directly owned 21,479 shares in the company, valued at approximately $713,102.80. This trade represents a 36.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin Juvenal sold 9,050 shares of Castle Biosciences stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total value of $317,112.00. Following the sale, the insider directly owned 66,914 shares in the company, valued at $2,344,666.56. The trade was a 11.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 132,300 shares of company stock valued at $4,531,018 in the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Castle Biosciences Trading Up 0.1%

NASDAQ CSTL opened at $33.40 on Friday. The firm’s fifty day moving average price is $34.39 and its two-hundred day moving average price is $28.20. The company has a quick ratio of 5.12, a current ratio of 5.28 and a debt-to-equity ratio of 0.01. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. The company had revenue of $101.95 million during the quarter, compared to analysts’ expectations of $92.76 million. As a group, sell-side analysts forecast that Castle Biosciences, Inc. will post -0.82 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. BTIG Research upped their price objective on Castle Biosciences from $44.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 9th. Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. KeyCorp lifted their target price on Castle Biosciences from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. Robert W. Baird boosted their target price on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Monday, November 9th. Finally, Mizuho began coverage on Castle Biosciences in a research note on Thursday, October 29th. They set an “outperform” rating and a $60.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $46.50.

Read Our Latest Research Report on CSTL

Castle Biosciences Profile

(Free Report)

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.

Featured Articles

Institutional Ownership by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.